ASCO GU 2022

Role of PARPi in urothelial cancer

ADC in bladder cancer: defining the future!

Neoadjuvant therapy in UTUC: Good options for selected patients

PARPi in urothelial cancer: DFS advantage for the DDR+, OS data pending.

Patient selection for bladder preservation

Exciting data supports trimodality therapy

Ongoing immunotherapy innovation for mCRPC

HER2 ERBB2 – entering precision oncology

Follow-up data confirm OS benefit across subgroups

Patient selection for adjuvant Nivolumab (TPS vs. CPS)

IO escalation results in improved response in met. TCC.

ADC shape the therapy landscape in urothelial cancer

ADCs will be step-changing in urothelial cancers

Mature data confirm efficacy of maintenance avelumab as standard of care

Not practice changing, but hypothesis generating.

Theranostics – Presence and future: Vision, PSMAfore, PSMAAddition, TheraP

Do we need testing? Which biomarkers are of relevance?

Enza beyond progression? Practice changing or not?

The future of genetic testing. Somatic vs. germline? International perspectives

Triplet vs. doublet: Which patients should we consider?

Is biomarker development taking a back seat in prostate cancer?

Is docetaxel still needed for hormone sensitive mCRPC?

Addition of darolutamide improves OS in met. hormone-sensitive PC

Subgroup analyses confirm the importance of oral daily GnRH Antagonist - relugolix

New therapies and molecular targets in prostate cancer

PSMA and FDG PET as biomarkers for response to LuPSMA

PSA response correlates with OS and benefits in QoL

Triplet-therapy as a novel treatment option

PROpel & Magnitude: who wins the race?

DARO in triplet therapy for CRPC

Should we use arbiraterone and olaparib as 1st line treatment of mCRPC?

HRR testing: MAGNITUDE vs. PROpel

Where do PROpel and Magnitude agree?

Exciting new compound for mCRPC

Should we use arbiraterone and niraparib as 1st line treatment of mCRPC with BRCA1/2 mutation?

The need for biomarker panels in biopsy decision making

How to improve PSMA based radioligand therapy

Is the dual hormone-backbone the future?

PRESIDE indicates benefit of continuation ENZA + ADT

The importance of conducting HCRA

Neoadjuvant IO+TKI Treatment: We need more data on efficient IO/TKI combinations

Treatment options following adjuvant PD1 Therapy: Uncertainty of choices!

Thoughts on first line treatment options following ASCO GU 2022

Adjuvant PD1 Therapy confirms significant benefit for high-risk patients. An individual risk benefit assessment is required!

Consistent OS benefit confirmed. Consider overtreatment vs. undertreatment!

Adjuvant Pembroluzimab update in kidney cancer

Frontline treatment of metastatic kidney cancer

Neoadjuvant avelumab/axitinib - NeoAvAx

Nivo montoherapy followed by Nivi-Ipi resuce

Update in neoadjuvant therapy for kidney cancer

Update in adjuvant therapy for kidney cancer

Data gap in 2nd line RCC: what’s new?

CheckMate final OS Follow Up and health related QoL

Microbioma modification and checkpoint inhibition